

CHEMOTHERAPY EXPERT ADVISORY GROUP
(Incorporating Network Pharmacy and chemotherapy Nursing Group)

Monday 12 March 2018, 1:30pm to 3.30pm Evolve Business Centre

AGENDA

1a	Welcome & Apologies		
1b	Previous Minutes – 20.11.17		ENC 01
1c	Terms of Reference -previous circulated info only		ENC 02
1d	Outstanding matters from previous minutes I. Community Chemotherapy – local models II. Cancer Vanguard Denusomab Model (Amgen) III. DPD Death and Investigation (Northumbria)- protocol updates with warning & Consent	AM All SW	
2	SPECIFIC ISSUES ARISING		
2a	Adjuvant-bisphosphonates in early breast cancer	All/CP	ENC 03
2b	Capacity Workshop- Sat 21st April	WA/P	ENC 04
2c	Cancer Alliance Update I. One Year On Event II. Chair of Group term of office	AM AM/SW	
2d	Chemotherapy E-Prescribing Progress I. Chemocare North II. Sunderland III. Chemocare South	MB/DB MR CP	
2e	PIP group Pharna Challenge	AM	
3	WORKPLAN ITEMS		
3a	Review and Update Workplan	All	ENC 05
3b	Local Chemotherapy Service Update	All	
3c	Capacity Planning and Horizon Scanning	SW	
4	COMMISSIONING / NHS ENGLAND		
4a	Specialized Commissioning Update	WH	
4b	National clinical policy development process & Removal local One-Off Policy	WH/SW	ENC 06, ENC07
4c	CDF and National Chemotherapy CRG Update	SW	
4d	Biosimilar Trastuzumab	WH/SW	
4e	Local Approved Regimen List	SW	ENC 08
4f	List of NHS E approved treatments (for Info)	SW	ENC 09

5	POLICY & PROTOCOLS		
5a	Policy Document Control Form & Project report	CB	To Be Tabled
5b	Antiemetic Policy (<i>for Info and Approval</i>)	DB/SW	ENC 10
5c	Network Chemotherapy Nurse Training & Training Competency Policies (<i>for Info and Approval</i>)	AE/WA	ENC 11, ENC 12
5d	Non-Medical Prescribing Policy (<i>for discussion</i>)	SW	ENC 13
5e	Oral Chemo Policy (<i>for Info and Approval</i>)	SW	ENC 14
5f	Adult Venous Access and (CVAD) (<i>for Info and Approval</i>)	WA	ENC 15
6	CLINICAL GOVERNANCE ISSUES		
	To be tabled at meeting		
7	SACT DATASET (standing agenda item)		
7a	SACT local Reports Available	SW	
7b	Local Trust SACT databases	SW	
8	PATIENT EXPERIENCE None Noted		
9	DRUG/ REGIMEN ISSUES		
9a	IO Toxicity Advice	SW	ENC 16
9b	Daratumumab 1st cycle prolonged infusion	SW	
9c	Myeloma 1st line treatment Definition	SW/MR	
9b	Fuvestrant Commissioned Use clarification	SW	
10	ANY OTHER BUSINESS		
10a	For Info Only UK Chemotherapy Board 31.01.18	WA/SW	ENC 17
10b	For Info Only Chemotherapy CRG 10.01.18	WA/SW	
10c	Chemo Nurse Issues (not already on agenda)	MR	
10d	Chemo Pharmacy Issues (not already on agenda)	CP	
Date Next Meeting: Monday 10 September, 1.30-3.30, Evolve Business Centre			